01/03/2011 egrated healthcare Topics addressed What is - PDF document

01/03/2011 egrated healthcare Topics addressed • What is nanomedicine? • Examples of applications in oncology Nanomedicine • Role of Europe’s FP7 NMP programme A golden opportunity for the UK A ld t it f th UK Nanomedicine – Int • Opportunities for the UK Terry Wilkins Yorkshire Forward Professor of Nanomanufacturing Innovation Chair of European Commission’s Expert Advisory Group for Nano-, Materials- & Production- Technologies NMP RTD Programme t.a.wilkins@leeds.ac.uk egrated healthcare egrated healthcare Theranostic Nanoparticle* In Vitro Clinical Diagnostic Nanobiosensor ( A -components) Non-classical drugs (APIs) for delivery into cells and intracellular trafficking. A peptide aptamer is a molecule that binds specifically to a target (e.g. aptamer pep9 binds to protein CDK2 - involved in cell cycles). ( B -lipid components), protection against short- term-degradation ( C -stealth/ biocompatibility polymer layer components) and delivery to target cells Nanomedicine – Int Nanomedicine – Int ( D -biological targeting ligand components). 50 nm Enables combined delivery of : 1. More effective and less toxic drugs - E.g. short interfering RNA (SiRNA) 2. Multiple imaging agents a b c c Aptamer (pep9) is inserted in a protein scaffold (STM). A cysteine group binds to electrode and changes the impedance between electrode and fluid changes * Miller A M and Thanou M, Kings College London G Davies, E Linfield, C Walti & S Evans et al., Journal of Biology 7, 3 (2008). egrated healthcare egrated healthcare Nanomedicine Strategy for GI &GU Cancers Nanomedicine-enabled Laparoscopic Surgery In vitro diagnostics (IVD) Super paramagnetic iron oxide nanoparticles Serum biomarkers profiling sensor chip In vitro proof Label-free Label-free Spintronics of diagnosis Multi-analyte Multi-analyte High-sensitivity Serum early Sensor chips Sensor chips diagnosis sensor Sensor oitation ection Theranostic delivery agents eds eds Patients' Nee Patients' Nee Post-project explo Nanomedicine – Int Nanomedicine – Int Biomarkers Sele ABCD Multi-function Nanoparticle nanoparticles for Pre-clinical in vivo delivery of: In vivo • Imaging agents proof • RNAi drugs of • Classical drugs Efficacy Attachment between magnetised tissue and the Pre-clinical magnetic probe Toxicology Fluorescent Nano-enabled Studies & Magnetic minimal-invasive nanoparticles surgical devices Magnetic retraction Fluorescence imaging of Minimal invasive surgery Less stress to organs Tumours guides resection * Leeds Institute of Molecular Medicine, Nanomanufacturing Institute & Leeds NHS Teaching Hospital Trust + Partners Suh D et al 2009 & Neville A, Jayne D, 2010 1

01/03/2011 egrated healthcare egrated healthcare NMP Strategic and Annual Planning Processes Nanomedicine European Technology Platform EC NMP Directorate a. a. Diagnostic sensors Diagnostic sensors a. Cardiovascular disease, b. b. Imaging Imaging b. Cancer, Industry Member c. c. Bone & Tissue Bone & Tissue & Research States c. Planning Musculoskeletal disorders, 36 Industry sectors Inputs Annual Work Programme Engineering Engineering Expert Programme d. Neurodegenerative diseases European Advisory Group Committee d. d. Surgery Surgery e. Diabetes Technology Platforms e. e. Drug delivery Drug delivery f. Bacterial and viral applications FP6/7 Project f f f. f. W W Wound care Wound care d d Portfolio Portfolio NMP FP7 NMP FP7 Annual Annual Nanomedicine – Int Nanomedicine – Int Strategic Implementation g. g. Antiviral applications Antiviral applications Plan Plan 2007-12 Foresight Reports h. h. Health & safety Health & safety Other Stakeholders • Initial plan EC Interservice • Mid-term review Committees • FP8 preparation − 62 Healthcare companies Calls Published ~July − 78 Universities & RTOs Budget = €3.5 billion 2006-12 − 10 Other (EC, Hospitals) Nanomedicine ’ – European Technology Platform, NB : ETP Nanomedicine is one of the 3 most influential ETPs Expert Report & Road Maps, 2009 Healthcare www.etp-nanomedicine.eu egrated healthcare egrated healthcare Nanomedicine: 1740 Publications in Pubmed FP7 NMP Nanomedicine Expenditure (2006-10) 200 Total = 262.8 € Million 150 129.8 Drug Delivery Millions 100.7 Cancer 100 M Nanomedicine – Int Nanomedicine – Int Bioengineering € 50 31.6 CVS 2.7 0 Other Theranostics Nano- Nano-bio Support actions regenerative enabling (e.g. ERA Net) medicine platforms egrated healthcare egrated healthcare Summary How ready is nanotechnology for oncology applications? • Nanomedicine has made huge progress in the last 5 ‐ years • Benefits for patients, healthcare providers & Pharma (pipeline & jobs) • EC and Nanomedicine ‐ ETP strategic approach has been key 2004 “…. not mature enough to be useful in • UK science is strong ‐ built on £16.2 million (10 EPSRC grants) in 2008 cancer research”….. ICRF review led by Sir Paul Nurse ICRF review led by Sir Paul Nurse • UK could take a leadership role in Europe supported by: UK ld t k l d hi l i E t d b Nanomedicine – Int Nanomedicine – Int Royal Society & Royal Academy of Engineering � 2010 “…. Now ready to aid significant advances UK Pharma companies � in both research and clinical practice � GE’s leadership of the ETP in oncology ”….. EU’s largest teaching hospital (Leeds NHS Trust) � Personal communication by Sir Paul Nurse • A revision of the UK’s nanomedicine research strategy is advised: Move to platform grants to integrate UK research base � EU engagement plan to support UK research in FP8 � (public:public & public:private co-funding partnerships) 2

01/03/2011 egrated healthcare Open Innovation & Nanomedicine Nanomedicine – Int H W Chesbrough, W Vanhaverbeke, J West, Oxford University Press, 2006 • All top US, EU and UK pharma companies have this game plan • Highly suitable for nanomedicine translational research • Nanomedicine + non-classical drugs could overcome pharma pipeline problem 3